Maravai LifeSciences - MRVI Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRVI shares.
View MRVI analyst ratings or view top-rated stocks.

8 equities research analysts have issued 12-month price objectives for Maravai LifeSciences' shares. Their MRVI share price forecasts range from $16.00 to $32.00. On average, they predict the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 56.4% from the stock's current price.
View analysts price targets for MRVI or view top-rated stocks among Wall Street analysts.

Maravai LifeSciences' stock was trading at $14.31 on January 1st, 2023. Since then, MRVI shares have increased by 2.8% and is now trading at $14.71.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our MRVI earnings forecast.

Maravai LifeSciences will be holding an earnings conference call on Wednesday, February 22nd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) issued its quarterly earnings results on Wednesday, November, 10th. The company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.35 by $0.09. The firm earned $204.81 million during the quarter, compared to the consensus estimate of $199.68 million. Maravai LifeSciences had a trailing twelve-month return on equity of 69.19% and a net margin of 26.29%.

Maravai LifeSciences issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of $1.76-$1.80 for the period, compared to the consensus estimate of $1.76. The company issued revenue guidance of $880.00 million-$890.00 million, compared to the consensus revenue estimate of $889.97 million.

(MRVI) raised $1.3 billion in an initial public offering (IPO) on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Maravai LifeSciences trades on the NASDAQ under the ticker symbol "MRVI."

Maravai LifeSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vaughan Nelson Investment Management L.P. (0.49%), Curi Wealth Management LLC (0.36%), Natixis Advisors L.P. (0.18%), State of Alaska Department of Revenue (0.15%), Bank Julius Baer & Co. Ltd Zurich (0.09%) and New York State Common Retirement Fund (0.06%).

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRVI stock can currently be purchased for approximately $14.71.

Maravai LifeSciences (NASDAQ:MRVI) has a market capitalization of $3.75 billion and generates $906.73 million in revenue each year. The company earns $182.04 million in net income (profit) each year or $1.79 on an earnings per share basis.

The company employs 470 workers across the globe.

Maravai LifeSciences' mailing address is 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.maravai.com. The company can be reached via phone at 858-546-0004 or via email at ir@maravai.com.